nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.279	0.58	CiPCiCtD
Bosutinib—P-Glycoprotein Inhibitors—Vemurafenib—melanoma	0.201	0.42	CiPCiCtD
Bosutinib—PKMYT1—melanoma	0.0579	0.182	CbGaD
Bosutinib—SYK—melanoma	0.0492	0.154	CbGaD
Bosutinib—CDK2—melanoma	0.0401	0.126	CbGaD
Bosutinib—EPHA2—melanoma	0.0401	0.126	CbGaD
Bosutinib—MAP2K2—melanoma	0.0373	0.117	CbGaD
Bosutinib—PTK2B—melanoma	0.0283	0.0887	CbGaD
Bosutinib—MAP2K1—melanoma	0.0283	0.0887	CbGaD
Bosutinib—ERBB4—melanoma	0.0259	0.0811	CbGaD
Bosutinib—EGFR—Docetaxel—melanoma	0.0198	0.665	CbGbCtD
Bosutinib—EGFR—melanoma	0.00903	0.0283	CbGaD
Bosutinib—CYP3A4—Temozolomide—melanoma	0.00376	0.126	CbGbCtD
Bosutinib—ABCB1—melanoma	0.00275	0.00861	CbGaD
Bosutinib—ABCB1—Dactinomycin—melanoma	0.00228	0.0766	CbGbCtD
Bosutinib—CYP3A4—Vemurafenib—melanoma	0.00206	0.0691	CbGbCtD
Bosutinib—ABCB1—Docetaxel—melanoma	0.00118	0.0396	CbGbCtD
Bosutinib—CYP3A4—Docetaxel—melanoma	0.000707	0.0237	CbGbCtD
Bosutinib—WEE1—Paclitaxel—Docetaxel—melanoma	0.000617	0.484	CbGdCrCtD
Bosutinib—CDK2—Paclitaxel—Docetaxel—melanoma	0.000503	0.395	CbGdCrCtD
Bosutinib—Vandetanib—KDR—melanoma	0.000304	0.257	CrCbGaD
Bosutinib—Vandetanib—VEGFA—melanoma	0.000258	0.218	CrCbGaD
Bosutinib—Liver injury—Temozolomide—melanoma	0.000235	0.00664	CcSEcCtD
Bosutinib—Febrile neutropenia—Docetaxel—melanoma	0.000218	0.00618	CcSEcCtD
Bosutinib—Vandetanib—EGFR—melanoma	0.000218	0.184	CrCbGaD
Bosutinib—Infestation NOS—Vemurafenib—melanoma	0.000216	0.00611	CcSEcCtD
Bosutinib—Infestation—Vemurafenib—melanoma	0.000216	0.00611	CcSEcCtD
Bosutinib—Gefitinib—EGFR—melanoma	0.000207	0.175	CrCbGaD
Bosutinib—Respiratory failure—Temozolomide—melanoma	0.000201	0.00569	CcSEcCtD
Bosutinib—Oedema peripheral—Vemurafenib—melanoma	0.000191	0.00541	CcSEcCtD
Bosutinib—Connective tissue disorder—Vemurafenib—melanoma	0.000191	0.00539	CcSEcCtD
Bosutinib—Erythema multiforme—Vemurafenib—melanoma	0.000184	0.00519	CcSEcCtD
Bosutinib—Cardiac disorder—Vemurafenib—melanoma	0.00018	0.00509	CcSEcCtD
Bosutinib—Mediastinal disorder—Vemurafenib—melanoma	0.000175	0.00495	CcSEcCtD
Bosutinib—Pleural effusion—Docetaxel—melanoma	0.000172	0.00485	CcSEcCtD
Bosutinib—Hepatotoxicity—Docetaxel—melanoma	0.00017	0.00481	CcSEcCtD
Bosutinib—Malnutrition—Vemurafenib—melanoma	0.000169	0.00478	CcSEcCtD
Bosutinib—Dysgeusia—Vemurafenib—melanoma	0.000166	0.00468	CcSEcCtD
Bosutinib—Back pain—Vemurafenib—melanoma	0.000164	0.00462	CcSEcCtD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—melanoma	0.000154	0.121	CbGdCrCtD
Bosutinib—MAP3K12—eye—melanoma	0.000152	0.00391	CbGeAlD
Bosutinib—TLK1—head—melanoma	0.000151	0.00389	CbGeAlD
Bosutinib—PRKCQ—head—melanoma	0.000149	0.00384	CbGeAlD
Bosutinib—MAP2K1—eye—melanoma	0.000149	0.00383	CbGeAlD
Bosutinib—Chest discomfort—Docetaxel—melanoma	0.000149	0.0042	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Carmustine—melanoma	0.000148	0.0042	CcSEcCtD
Bosutinib—CAMK1D—mammalian vulva—melanoma	0.000148	0.00381	CbGeAlD
Bosutinib—CSK—eye—melanoma	0.000148	0.0038	CbGeAlD
Bosutinib—PDGFRB—blood vessel—melanoma	0.000148	0.0038	CbGeAlD
Bosutinib—Cough—Vemurafenib—melanoma	0.000148	0.00417	CcSEcCtD
Bosutinib—SIK2—head—melanoma	0.000147	0.00379	CbGeAlD
Bosutinib—CSNK1A1—eye—melanoma	0.000147	0.00378	CbGeAlD
Bosutinib—CLK1—eye—melanoma	0.000146	0.00376	CbGeAlD
Bosutinib—CLK1—retina—melanoma	0.000145	0.00372	CbGeAlD
Bosutinib—Myalgia—Vemurafenib—melanoma	0.000144	0.00407	CcSEcCtD
Bosutinib—Arthralgia—Vemurafenib—melanoma	0.000144	0.00407	CcSEcCtD
Bosutinib—PKMYT1—head—melanoma	0.000143	0.00369	CbGeAlD
Bosutinib—CAMK2G—eye—melanoma	0.000143	0.00369	CbGeAlD
Bosutinib—Face oedema—Carmustine—melanoma	0.000143	0.00405	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000143	0.00404	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000143	0.00404	CcSEcCtD
Bosutinib—FER—mammalian vulva—melanoma	0.000142	0.00365	CbGeAlD
Bosutinib—CLK3—head—melanoma	0.00014	0.0036	CbGeAlD
Bosutinib—Pancytopenia—Bleomycin—melanoma	0.00014	0.00395	CcSEcCtD
Bosutinib—BMPR2—skin of body—melanoma	0.000139	0.00358	CbGeAlD
Bosutinib—MAP4K1—mammalian vulva—melanoma	0.000139	0.00357	CbGeAlD
Bosutinib—Blood bilirubin increased—Docetaxel—melanoma	0.000139	0.00393	CcSEcCtD
Bosutinib—Face oedema—Temozolomide—melanoma	0.000139	0.00391	CcSEcCtD
Bosutinib—BTK—mammalian vulva—melanoma	0.000138	0.00356	CbGeAlD
Bosutinib—Anaphylactic shock—Vemurafenib—melanoma	0.000138	0.0039	CcSEcCtD
Bosutinib—Infection—Vemurafenib—melanoma	0.000137	0.00387	CcSEcCtD
Bosutinib—EPHB2—head—melanoma	0.000137	0.00352	CbGeAlD
Bosutinib—PHKG1—head—melanoma	0.000137	0.00352	CbGeAlD
Bosutinib—Nervous system disorder—Vemurafenib—melanoma	0.000135	0.00382	CcSEcCtD
Bosutinib—CSNK1E—retina—melanoma	0.000135	0.00347	CbGeAlD
Bosutinib—Skin disorder—Vemurafenib—melanoma	0.000134	0.00379	CcSEcCtD
Bosutinib—SRMS—head—melanoma	0.000134	0.00344	CbGeAlD
Bosutinib—Respiratory failure—Docetaxel—melanoma	0.000134	0.00378	CcSEcCtD
Bosutinib—Dehydration—Temozolomide—melanoma	0.000133	0.00377	CcSEcCtD
Bosutinib—TXK—head—melanoma	0.000133	0.00341	CbGeAlD
Bosutinib—Pneumonia—Bleomycin—melanoma	0.000132	0.00373	CcSEcCtD
Bosutinib—EPHA8—head—melanoma	0.000131	0.00337	CbGeAlD
Bosutinib—ULK3—eye—melanoma	0.000131	0.00337	CbGeAlD
Bosutinib—Pancytopenia—Dactinomycin—melanoma	0.00013	0.00368	CcSEcCtD
Bosutinib—ULK3—retina—melanoma	0.00013	0.00334	CbGeAlD
Bosutinib—MAP2K1—skin of body—melanoma	0.00013	0.00333	CbGeAlD
Bosutinib—STK35—skin of body—melanoma	0.00013	0.00333	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000129	0.00365	CcSEcCtD
Bosutinib—CSK—skin of body—melanoma	0.000129	0.00331	CbGeAlD
Bosutinib—SYK—head—melanoma	0.000129	0.00331	CbGeAlD
Bosutinib—Neutropenia—Dactinomycin—melanoma	0.000128	0.00362	CcSEcCtD
Bosutinib—CSNK1A1—skin of body—melanoma	0.000128	0.00329	CbGeAlD
Bosutinib—MAP3K7—retina—melanoma	0.000128	0.00329	CbGeAlD
Bosutinib—TBK1—eye—melanoma	0.000128	0.00328	CbGeAlD
Bosutinib—CDK2—head—melanoma	0.000127	0.00328	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000127	0.00358	CcSEcCtD
Bosutinib—STK26—head—melanoma	0.000126	0.00325	CbGeAlD
Bosutinib—EPHB3—mammalian vulva—melanoma	0.000126	0.00324	CbGeAlD
Bosutinib—STK36—mammalian vulva—melanoma	0.000126	0.00324	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000126	0.00355	CcSEcCtD
Bosutinib—Fluid retention—Docetaxel—melanoma	0.000125	0.00353	CcSEcCtD
Bosutinib—MERTK—mammalian vulva—melanoma	0.000125	0.00321	CbGeAlD
Bosutinib—Pneumonia—Dactinomycin—melanoma	0.000123	0.00348	CcSEcCtD
Bosutinib—RPS6KB1—eye—melanoma	0.000123	0.00315	CbGeAlD
Bosutinib—MAP4K4—mammalian vulva—melanoma	0.000122	0.00315	CbGeAlD
Bosutinib—Pancytopenia—Carmustine—melanoma	0.000122	0.00344	CcSEcCtD
Bosutinib—RPS6KB1—retina—melanoma	0.000122	0.00313	CbGeAlD
Bosutinib—NUAK2—mammalian vulva—melanoma	0.000122	0.00312	CbGeAlD
Bosutinib—BCR—mammalian vulva—melanoma	0.000122	0.00312	CbGeAlD
Bosutinib—AXL—eye—melanoma	0.000121	0.00312	CbGeAlD
Bosutinib—WEE1—head—melanoma	0.000121	0.00311	CbGeAlD
Bosutinib—DMPK—head—melanoma	0.000121	0.00311	CbGeAlD
Bosutinib—MAP3K12—mammalian vulva—melanoma	0.000121	0.0031	CbGeAlD
Bosutinib—AXL—retina—melanoma	0.00012	0.00309	CbGeAlD
Bosutinib—Neutropenia—Carmustine—melanoma	0.00012	0.00339	CcSEcCtD
Bosutinib—Decreased appetite—Vemurafenib—melanoma	0.00012	0.00339	CcSEcCtD
Bosutinib—Bronchitis—Temozolomide—melanoma	0.000119	0.00337	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000119	0.00337	CcSEcCtD
Bosutinib—Fatigue—Vemurafenib—melanoma	0.000119	0.00336	CcSEcCtD
Bosutinib—CSNK1E—skin of body—melanoma	0.000119	0.00305	CbGeAlD
Bosutinib—Pancytopenia—Temozolomide—melanoma	0.000118	0.00333	CcSEcCtD
Bosutinib—CSK—mammalian vulva—melanoma	0.000117	0.00302	CbGeAlD
Bosutinib—SIK1—skin of body—melanoma	0.000117	0.003	CbGeAlD
Bosutinib—CSNK1A1—mammalian vulva—melanoma	0.000117	0.003	CbGeAlD
Bosutinib—Neutropenia—Temozolomide—melanoma	0.000116	0.00328	CcSEcCtD
Bosutinib—HCK—mammalian vulva—melanoma	0.000116	0.00298	CbGeAlD
Bosutinib—CLK1—mammalian vulva—melanoma	0.000116	0.00298	CbGeAlD
Bosutinib—STK25—head—melanoma	0.000116	0.00297	CbGeAlD
Bosutinib—Upper respiratory tract infection—Temozolomide—melanoma	0.000115	0.00326	CcSEcCtD
Bosutinib—Pneumonia—Carmustine—melanoma	0.000115	0.00325	CcSEcCtD
Bosutinib—EPHA3—head—melanoma	0.000115	0.00295	CbGeAlD
Bosutinib—ERBB3—skin of body—melanoma	0.000114	0.00294	CbGeAlD
Bosutinib—MAP2K2—skin of body—melanoma	0.000114	0.00293	CbGeAlD
Bosutinib—Agranulocytosis—Dactinomycin—melanoma	0.000114	0.00322	CcSEcCtD
Bosutinib—LRRK2—mammalian vulva—melanoma	0.000113	0.0029	CbGeAlD
Bosutinib—Renal failure—Carmustine—melanoma	0.000112	0.00318	CcSEcCtD
Bosutinib—EGFR—mammalian vulva—melanoma	0.000112	0.00289	CbGeAlD
Bosutinib—PLK2—head—melanoma	0.000112	0.00289	CbGeAlD
Bosutinib—SIK3—head—melanoma	0.000112	0.00287	CbGeAlD
Bosutinib—Pneumonia—Temozolomide—melanoma	0.000111	0.00314	CcSEcCtD
Bosutinib—PTK2—skin of body—melanoma	0.000111	0.00285	CbGeAlD
Bosutinib—Infestation—Temozolomide—melanoma	0.000111	0.00312	CcSEcCtD
Bosutinib—Infestation NOS—Temozolomide—melanoma	0.000111	0.00312	CcSEcCtD
Bosutinib—Hepatitis—Dactinomycin—melanoma	0.00011	0.0031	CcSEcCtD
Bosutinib—Body temperature increased—Vemurafenib—melanoma	0.000109	0.00308	CcSEcCtD
Bosutinib—CSNK1E—mammalian vulva—melanoma	0.000108	0.00278	CbGeAlD
Bosutinib—STK4—head—melanoma	0.000107	0.00276	CbGeAlD
Bosutinib—SIK1—mammalian vulva—melanoma	0.000106	0.00274	CbGeAlD
Bosutinib—IRAK4—mammalian vulva—melanoma	0.000106	0.00274	CbGeAlD
Bosutinib—CAMK1D—head—melanoma	0.000106	0.00273	CbGeAlD
Bosutinib—TLK1—lymph node—melanoma	0.000106	0.00272	CbGeAlD
Bosutinib—AXL—skin of body—melanoma	0.000106	0.00272	CbGeAlD
Bosutinib—PDGFRB—neck—melanoma	0.000106	0.00272	CbGeAlD
Bosutinib—EPHA4—mammalian vulva—melanoma	0.000105	0.00271	CbGeAlD
Bosutinib—STK24—head—melanoma	0.000105	0.0027	CbGeAlD
Bosutinib—Hepatobiliary disease—Temozolomide—melanoma	0.000105	0.00296	CcSEcCtD
Bosutinib—PRKCQ—lymph node—melanoma	0.000105	0.00269	CbGeAlD
Bosutinib—ULK3—mammalian vulva—melanoma	0.000104	0.00268	CbGeAlD
Bosutinib—MAP2K2—mammalian vulva—melanoma	0.000104	0.00268	CbGeAlD
Bosutinib—Erythema multiforme—Dactinomycin—melanoma	0.000104	0.00293	CcSEcCtD
Bosutinib—YES1—eye—melanoma	0.000103	0.00264	CbGeAlD
Bosutinib—MAP3K7—mammalian vulva—melanoma	0.000102	0.00263	CbGeAlD
Bosutinib—YES1—retina—melanoma	0.000102	0.00261	CbGeAlD
Bosutinib—FER—head—melanoma	0.000102	0.00261	CbGeAlD
Bosutinib—TYRO3—head—melanoma	0.000102	0.00261	CbGeAlD
Bosutinib—ALK—head—melanoma	0.000102	0.00261	CbGeAlD
Bosutinib—EPHA5—head—melanoma	0.000102	0.00261	CbGeAlD
Bosutinib—TAOK3—eye—melanoma	0.000101	0.0026	CbGeAlD
Bosutinib—Oedema peripheral—Carmustine—melanoma	0.000101	0.00286	CcSEcCtD
Bosutinib—TBK1—mammalian vulva—melanoma	0.000101	0.0026	CbGeAlD
Bosutinib—LYN—head—melanoma	0.000101	0.0026	CbGeAlD
Bosutinib—Connective tissue disorder—Carmustine—melanoma	0.000101	0.00285	CcSEcCtD
Bosutinib—TAOK3—retina—melanoma	0.0001	0.00258	CbGeAlD
Bosutinib—Renal impairment—Docetaxel—melanoma	0.0001	0.00283	CcSEcCtD
Bosutinib—MAP3K19—head—melanoma	9.95e-05	0.00256	CbGeAlD
Bosutinib—Hepatitis—Temozolomide—melanoma	9.93e-05	0.00281	CcSEcCtD
Bosutinib—IRAK1—mammalian vulva—melanoma	9.92e-05	0.00255	CbGeAlD
Bosutinib—Asthenia—Vemurafenib—melanoma	9.9e-05	0.0028	CcSEcCtD
Bosutinib—FYN—skin of body—melanoma	9.89e-05	0.00254	CbGeAlD
Bosutinib—SRC—eye—melanoma	9.87e-05	0.00254	CbGeAlD
Bosutinib—BMX—lymph node—melanoma	9.81e-05	0.00252	CbGeAlD
Bosutinib—DSTYK—lymph node—melanoma	9.81e-05	0.00252	CbGeAlD
Bosutinib—CLK3—lymph node—melanoma	9.81e-05	0.00252	CbGeAlD
Bosutinib—Urinary tract disorder—Temozolomide—melanoma	9.8e-05	0.00277	CcSEcCtD
Bosutinib—SRC—retina—melanoma	9.78e-05	0.00251	CbGeAlD
Bosutinib—Oedema peripheral—Temozolomide—melanoma	9.78e-05	0.00276	CcSEcCtD
Bosutinib—Pruritus—Vemurafenib—melanoma	9.76e-05	0.00276	CcSEcCtD
Bosutinib—Connective tissue disorder—Temozolomide—melanoma	9.75e-05	0.00276	CcSEcCtD
Bosutinib—TNK2—head—melanoma	9.75e-05	0.00251	CbGeAlD
Bosutinib—RPS6KB1—mammalian vulva—melanoma	9.73e-05	0.0025	CbGeAlD
Bosutinib—Urethral disorder—Temozolomide—melanoma	9.73e-05	0.00275	CcSEcCtD
Bosutinib—BLK—lymph node—melanoma	9.69e-05	0.00249	CbGeAlD
Bosutinib—LCK—mammalian vulva—melanoma	9.67e-05	0.00249	CbGeAlD
Bosutinib—FGR—mammalian vulva—melanoma	9.67e-05	0.00249	CbGeAlD
Bosutinib—MAP3K3—skin of body—melanoma	9.66e-05	0.00248	CbGeAlD
Bosutinib—AXL—mammalian vulva—melanoma	9.64e-05	0.00248	CbGeAlD
Bosutinib—CASK—lymph node—melanoma	9.58e-05	0.00246	CbGeAlD
Bosutinib—PHKG1—lymph node—melanoma	9.58e-05	0.00246	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Docetaxel—melanoma	9.54e-05	0.0027	CcSEcCtD
Bosutinib—Ill-defined disorder—Bleomycin—melanoma	9.5e-05	0.00269	CcSEcCtD
Bosutinib—ERBB4—head—melanoma	9.49e-05	0.00244	CbGeAlD
Bosutinib—STK3—head—melanoma	9.49e-05	0.00244	CbGeAlD
Bosutinib—EIF2AK1—lymph node—melanoma	9.48e-05	0.00244	CbGeAlD
Bosutinib—Anaemia—Bleomycin—melanoma	9.47e-05	0.00268	CcSEcCtD
Bosutinib—Diarrhoea—Vemurafenib—melanoma	9.44e-05	0.00267	CcSEcCtD
Bosutinib—Erythema multiforme—Temozolomide—melanoma	9.38e-05	0.00265	CcSEcCtD
Bosutinib—ROCK1—head—melanoma	9.36e-05	0.00241	CbGeAlD
Bosutinib—TXK—lymph node—melanoma	9.28e-05	0.00239	CbGeAlD
Bosutinib—SLK—mammalian vulva—melanoma	9.27e-05	0.00238	CbGeAlD
Bosutinib—Tinnitus—Temozolomide—melanoma	9.25e-05	0.00262	CcSEcCtD
Bosutinib—Malaise—Bleomycin—melanoma	9.24e-05	0.00261	CcSEcCtD
Bosutinib—Cardiac disorder—Temozolomide—melanoma	9.21e-05	0.0026	CcSEcCtD
Bosutinib—EPHB4—mammalian vulva—melanoma	9.21e-05	0.00237	CbGeAlD
Bosutinib—FES—lymph node—melanoma	9.19e-05	0.00236	CbGeAlD
Bosutinib—VRK2—lymph node—melanoma	9.19e-05	0.00236	CbGeAlD
Bosutinib—Leukopenia—Bleomycin—melanoma	9.17e-05	0.00259	CcSEcCtD
Bosutinib—Dizziness—Vemurafenib—melanoma	9.12e-05	0.00258	CcSEcCtD
Bosutinib—BMPR2—head—melanoma	9.1e-05	0.00234	CbGeAlD
Bosutinib—EPHA2—mammalian vulva—melanoma	9.03e-05	0.00232	CbGeAlD
Bosutinib—EPHB3—head—melanoma	9.02e-05	0.00232	CbGeAlD
Bosutinib—STK36—head—melanoma	9.02e-05	0.00232	CbGeAlD
Bosutinib—FYN—mammalian vulva—melanoma	9.02e-05	0.00232	CbGeAlD
Bosutinib—SYK—lymph node—melanoma	9.01e-05	0.00232	CbGeAlD
Bosutinib—TNIK—lymph node—melanoma	9.01e-05	0.00232	CbGeAlD
Bosutinib—Immune system disorder—Temozolomide—melanoma	8.97e-05	0.00253	CcSEcCtD
Bosutinib—Mediastinal disorder—Temozolomide—melanoma	8.95e-05	0.00253	CcSEcCtD
Bosutinib—Malnutrition—Carmustine—melanoma	8.94e-05	0.00253	CcSEcCtD
Bosutinib—Cough—Bleomycin—melanoma	8.94e-05	0.00253	CcSEcCtD
Bosutinib—CDK2—lymph node—melanoma	8.93e-05	0.0023	CbGeAlD
Bosutinib—MERTK—head—melanoma	8.92e-05	0.00229	CbGeAlD
Bosutinib—Dehydration—Docetaxel—melanoma	8.87e-05	0.00251	CcSEcCtD
Bosutinib—Ill-defined disorder—Dactinomycin—melanoma	8.86e-05	0.00251	CcSEcCtD
Bosutinib—CSF1R—eye—melanoma	8.86e-05	0.00228	CbGeAlD
Bosutinib—STK26—lymph node—melanoma	8.85e-05	0.00227	CbGeAlD
Bosutinib—Anaemia—Dactinomycin—melanoma	8.83e-05	0.0025	CcSEcCtD
Bosutinib—MAP4K5—mammalian vulva—melanoma	8.81e-05	0.00227	CbGeAlD
Bosutinib—MAP3K3—mammalian vulva—melanoma	8.81e-05	0.00227	CbGeAlD
Bosutinib—Vomiting—Vemurafenib—melanoma	8.77e-05	0.00248	CcSEcCtD
Bosutinib—MAP4K4—head—melanoma	8.76e-05	0.00225	CbGeAlD
Bosutinib—Chest pain—Bleomycin—melanoma	8.72e-05	0.00246	CcSEcCtD
Bosutinib—Myalgia—Bleomycin—melanoma	8.72e-05	0.00246	CcSEcCtD
Bosutinib—Abdominal pain upper—Docetaxel—melanoma	8.71e-05	0.00246	CcSEcCtD
Bosutinib—Rash—Vemurafenib—melanoma	8.7e-05	0.00246	CcSEcCtD
Bosutinib—BCR—head—melanoma	8.69e-05	0.00223	CbGeAlD
Bosutinib—Dermatitis—Vemurafenib—melanoma	8.69e-05	0.00246	CcSEcCtD
Bosutinib—Back pain—Carmustine—melanoma	8.65e-05	0.00244	CcSEcCtD
Bosutinib—Headache—Vemurafenib—melanoma	8.64e-05	0.00244	CcSEcCtD
Bosutinib—Malnutrition—Temozolomide—melanoma	8.64e-05	0.00244	CcSEcCtD
Bosutinib—MAP3K12—head—melanoma	8.63e-05	0.00222	CbGeAlD
Bosutinib—Discomfort—Bleomycin—melanoma	8.62e-05	0.00244	CcSEcCtD
Bosutinib—Malaise—Dactinomycin—melanoma	8.62e-05	0.00243	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Docetaxel—melanoma	8.59e-05	0.00243	CcSEcCtD
Bosutinib—SRC—skin of body—melanoma	8.59e-05	0.00221	CbGeAlD
Bosutinib—Leukopenia—Dactinomycin—melanoma	8.55e-05	0.00242	CcSEcCtD
Bosutinib—CHEK2—lymph node—melanoma	8.54e-05	0.0022	CbGeAlD
Bosutinib—Nasopharyngitis—Docetaxel—melanoma	8.53e-05	0.00241	CcSEcCtD
Bosutinib—WEE1—lymph node—melanoma	8.47e-05	0.00218	CbGeAlD
Bosutinib—DMPK—lymph node—melanoma	8.47e-05	0.00218	CbGeAlD
Bosutinib—Dysgeusia—Temozolomide—melanoma	8.46e-05	0.00239	CcSEcCtD
Bosutinib—MAP2K1—head—melanoma	8.46e-05	0.00217	CbGeAlD
Bosutinib—STK35—head—melanoma	8.46e-05	0.00217	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Docetaxel—melanoma	8.42e-05	0.00238	CcSEcCtD
Bosutinib—CSK—head—melanoma	8.4e-05	0.00216	CbGeAlD
Bosutinib—Anaphylactic shock—Bleomycin—melanoma	8.36e-05	0.00236	CcSEcCtD
Bosutinib—Oedema—Bleomycin—melanoma	8.36e-05	0.00236	CcSEcCtD
Bosutinib—Back pain—Temozolomide—melanoma	8.36e-05	0.00236	CcSEcCtD
Bosutinib—CSNK1A1—head—melanoma	8.35e-05	0.00215	CbGeAlD
Bosutinib—Infection—Bleomycin—melanoma	8.31e-05	0.00235	CcSEcCtD
Bosutinib—HCK—head—melanoma	8.29e-05	0.00213	CbGeAlD
Bosutinib—CLK1—head—melanoma	8.29e-05	0.00213	CbGeAlD
Bosutinib—Anaemia—Carmustine—melanoma	8.26e-05	0.00234	CcSEcCtD
Bosutinib—Nausea—Vemurafenib—melanoma	8.2e-05	0.00232	CcSEcCtD
Bosutinib—Thrombocytopenia—Bleomycin—melanoma	8.19e-05	0.00231	CcSEcCtD
Bosutinib—CAMK2G—head—melanoma	8.14e-05	0.00209	CbGeAlD
Bosutinib—BMP2K—head—melanoma	8.14e-05	0.00209	CbGeAlD
Bosutinib—YES1—mammalian vulva—melanoma	8.14e-05	0.00209	CbGeAlD
Bosutinib—Myalgia—Dactinomycin—melanoma	8.13e-05	0.0023	CcSEcCtD
Bosutinib—STK25—lymph node—melanoma	8.09e-05	0.00208	CbGeAlD
Bosutinib—LRRK2—head—melanoma	8.07e-05	0.00207	CbGeAlD
Bosutinib—STK10—mammalian vulva—melanoma	8.07e-05	0.00207	CbGeAlD
Bosutinib—Discomfort—Dactinomycin—melanoma	8.04e-05	0.00227	CcSEcCtD
Bosutinib—TAOK3—mammalian vulva—melanoma	8.03e-05	0.00207	CbGeAlD
Bosutinib—EPHA3—lymph node—melanoma	8.03e-05	0.00206	CbGeAlD
Bosutinib—Ill-defined disorder—Temozolomide—melanoma	8.02e-05	0.00227	CcSEcCtD
Bosutinib—Leukopenia—Carmustine—melanoma	8e-05	0.00226	CcSEcCtD
Bosutinib—Anaemia—Temozolomide—melanoma	7.99e-05	0.00226	CcSEcCtD
Bosutinib—PLK2—lymph node—melanoma	7.87e-05	0.00202	CbGeAlD
Bosutinib—PTK2B—head—melanoma	7.86e-05	0.00202	CbGeAlD
Bosutinib—PDGFRB—eye—melanoma	7.86e-05	0.00202	CbGeAlD
Bosutinib—Pancytopenia—Docetaxel—melanoma	7.83e-05	0.00221	CcSEcCtD
Bosutinib—SIK3—lymph node—melanoma	7.81e-05	0.00201	CbGeAlD
Bosutinib—Oedema—Dactinomycin—melanoma	7.8e-05	0.0022	CcSEcCtD
Bosutinib—Malaise—Temozolomide—melanoma	7.79e-05	0.0022	CcSEcCtD
Bosutinib—Infection—Dactinomycin—melanoma	7.75e-05	0.00219	CcSEcCtD
Bosutinib—Leukopenia—Temozolomide—melanoma	7.73e-05	0.00219	CcSEcCtD
Bosutinib—CSNK1E—head—melanoma	7.73e-05	0.00199	CbGeAlD
Bosutinib—Neutropenia—Docetaxel—melanoma	7.71e-05	0.00218	CcSEcCtD
Bosutinib—CSF1R—skin of body—melanoma	7.71e-05	0.00198	CbGeAlD
Bosutinib—Thrombocytopenia—Dactinomycin—melanoma	7.63e-05	0.00216	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Bleomycin—melanoma	7.62e-05	0.00215	CcSEcCtD
Bosutinib—SIK1—head—melanoma	7.61e-05	0.00196	CbGeAlD
Bosutinib—IRAK4—head—melanoma	7.61e-05	0.00196	CbGeAlD
Bosutinib—Myalgia—Carmustine—melanoma	7.61e-05	0.00215	CcSEcCtD
Bosutinib—Chest pain—Carmustine—melanoma	7.61e-05	0.00215	CcSEcCtD
Bosutinib—Cough—Temozolomide—melanoma	7.54e-05	0.00213	CcSEcCtD
Bosutinib—EPHA4—head—melanoma	7.54e-05	0.00194	CbGeAlD
Bosutinib—STK4—lymph node—melanoma	7.52e-05	0.00193	CbGeAlD
Bosutinib—ERBB3—head—melanoma	7.46e-05	0.00192	CbGeAlD
Bosutinib—Dyspnoea—Bleomycin—melanoma	7.45e-05	0.00211	CcSEcCtD
Bosutinib—ULK3—head—melanoma	7.44e-05	0.00191	CbGeAlD
Bosutinib—MAP2K2—head—melanoma	7.44e-05	0.00191	CbGeAlD
Bosutinib—CAMK1D—lymph node—melanoma	7.43e-05	0.00191	CbGeAlD
Bosutinib—Pneumonia—Docetaxel—melanoma	7.4e-05	0.00209	CcSEcCtD
Bosutinib—MAP3K2—head—melanoma	7.39e-05	0.0019	CbGeAlD
Bosutinib—Arthralgia—Temozolomide—melanoma	7.36e-05	0.00208	CcSEcCtD
Bosutinib—Myalgia—Temozolomide—melanoma	7.36e-05	0.00208	CcSEcCtD
Bosutinib—Infestation NOS—Docetaxel—melanoma	7.35e-05	0.00208	CcSEcCtD
Bosutinib—Infestation—Docetaxel—melanoma	7.35e-05	0.00208	CcSEcCtD
Bosutinib—STK24—lymph node—melanoma	7.35e-05	0.00189	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	7.31e-05	0.00206	CcSEcCtD
Bosutinib—Oedema—Carmustine—melanoma	7.3e-05	0.00206	CcSEcCtD
Bosutinib—Discomfort—Temozolomide—melanoma	7.27e-05	0.00205	CcSEcCtD
Bosutinib—Decreased appetite—Bleomycin—melanoma	7.27e-05	0.00205	CcSEcCtD
Bosutinib—Infection—Carmustine—melanoma	7.25e-05	0.00205	CcSEcCtD
Bosutinib—PTK2—head—melanoma	7.24e-05	0.00186	CbGeAlD
Bosutinib—TBK1—head—melanoma	7.24e-05	0.00186	CbGeAlD
Bosutinib—Renal failure—Docetaxel—melanoma	7.23e-05	0.00204	CcSEcCtD
Bosutinib—MAP2K5—mammalian vulva—melanoma	7.2e-05	0.00185	CbGeAlD
Bosutinib—Pain—Bleomycin—melanoma	7.15e-05	0.00202	CcSEcCtD
Bosutinib—Thrombocytopenia—Carmustine—melanoma	7.14e-05	0.00202	CcSEcCtD
Bosutinib—FER—lymph node—melanoma	7.11e-05	0.00183	CbGeAlD
Bosutinib—ALK—lymph node—melanoma	7.11e-05	0.00183	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Dactinomycin—melanoma	7.1e-05	0.00201	CcSEcCtD
Bosutinib—Oedema—Temozolomide—melanoma	7.05e-05	0.00199	CcSEcCtD
Bosutinib—Anaphylactic shock—Temozolomide—melanoma	7.05e-05	0.00199	CcSEcCtD
Bosutinib—CSF1R—mammalian vulva—melanoma	7.03e-05	0.00181	CbGeAlD
Bosutinib—Infection—Temozolomide—melanoma	7.01e-05	0.00198	CcSEcCtD
Bosutinib—ABL1—eye—melanoma	7e-05	0.0018	CbGeAlD
Bosutinib—MAP4K1—lymph node—melanoma	6.96e-05	0.00179	CbGeAlD
Bosutinib—RPS6KB1—head—melanoma	6.96e-05	0.00179	CbGeAlD
Bosutinib—Hepatobiliary disease—Docetaxel—melanoma	6.95e-05	0.00197	CcSEcCtD
Bosutinib—ABL1—retina—melanoma	6.94e-05	0.00178	CbGeAlD
Bosutinib—Vandetanib—ALB—melanoma	6.93e-05	0.0585	CrCbGaD
Bosutinib—BTK—lymph node—melanoma	6.93e-05	0.00178	CbGeAlD
Bosutinib—FGR—head—melanoma	6.92e-05	0.00178	CbGeAlD
Bosutinib—Nervous system disorder—Temozolomide—melanoma	6.92e-05	0.00195	CcSEcCtD
Bosutinib—Thrombocytopenia—Temozolomide—melanoma	6.9e-05	0.00195	CcSEcCtD
Bosutinib—AXL—head—melanoma	6.89e-05	0.00177	CbGeAlD
Bosutinib—Feeling abnormal—Bleomycin—melanoma	6.89e-05	0.00195	CcSEcCtD
Bosutinib—Agranulocytosis—Docetaxel—melanoma	6.86e-05	0.00194	CcSEcCtD
Bosutinib—Skin disorder—Temozolomide—melanoma	6.85e-05	0.00194	CcSEcCtD
Bosutinib—PDGFRB—skin of body—melanoma	6.84e-05	0.00176	CbGeAlD
Bosutinib—TNK2—lymph node—melanoma	6.83e-05	0.00176	CbGeAlD
Bosutinib—Decreased appetite—Dactinomycin—melanoma	6.78e-05	0.00192	CcSEcCtD
Bosutinib—MAP4K2—lymph node—melanoma	6.73e-05	0.00173	CbGeAlD
Bosutinib—Fatigue—Dactinomycin—melanoma	6.72e-05	0.0019	CcSEcCtD
Bosutinib—Pain—Dactinomycin—melanoma	6.67e-05	0.00188	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Carmustine—melanoma	6.65e-05	0.00188	CcSEcCtD
Bosutinib—STK3—lymph node—melanoma	6.64e-05	0.00171	CbGeAlD
Bosutinib—Urticaria—Bleomycin—melanoma	6.64e-05	0.00188	CcSEcCtD
Bosutinib—Body temperature increased—Bleomycin—melanoma	6.61e-05	0.00187	CcSEcCtD
Bosutinib—Hepatitis—Docetaxel—melanoma	6.6e-05	0.00187	CcSEcCtD
Bosutinib—Gefitinib—ALB—melanoma	6.59e-05	0.0556	CrCbGaD
Bosutinib—Urinary tract disorder—Docetaxel—melanoma	6.52e-05	0.00184	CcSEcCtD
Bosutinib—Dyspnoea—Carmustine—melanoma	6.51e-05	0.00184	CcSEcCtD
Bosutinib—Oedema peripheral—Docetaxel—melanoma	6.5e-05	0.00184	CcSEcCtD
Bosutinib—Connective tissue disorder—Docetaxel—melanoma	6.49e-05	0.00183	CcSEcCtD
Bosutinib—Urethral disorder—Docetaxel—melanoma	6.47e-05	0.00183	CcSEcCtD
Bosutinib—EPHA2—head—melanoma	6.46e-05	0.00166	CbGeAlD
Bosutinib—FYN—head—melanoma	6.45e-05	0.00166	CbGeAlD
Bosutinib—Feeling abnormal—Dactinomycin—melanoma	6.42e-05	0.00182	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Temozolomide—melanoma	6.42e-05	0.00182	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dactinomycin—melanoma	6.38e-05	0.0018	CcSEcCtD
Bosutinib—BMPR2—lymph node—melanoma	6.37e-05	0.00164	CbGeAlD
Bosutinib—Decreased appetite—Carmustine—melanoma	6.34e-05	0.00179	CcSEcCtD
Bosutinib—STK36—lymph node—melanoma	6.32e-05	0.00162	CbGeAlD
Bosutinib—EPHB3—lymph node—melanoma	6.32e-05	0.00162	CbGeAlD
Bosutinib—MAP4K5—head—melanoma	6.3e-05	0.00162	CbGeAlD
Bosutinib—MAP3K3—head—melanoma	6.3e-05	0.00162	CbGeAlD
Bosutinib—Gastrointestinal disorder—Carmustine—melanoma	6.3e-05	0.00178	CcSEcCtD
Bosutinib—Dyspnoea—Temozolomide—melanoma	6.29e-05	0.00178	CcSEcCtD
Bosutinib—Gefitinib—ABCB1—melanoma	6.28e-05	0.0531	CrCbGaD
Bosutinib—MERTK—lymph node—melanoma	6.25e-05	0.00161	CbGeAlD
Bosutinib—Erythema multiforme—Docetaxel—melanoma	6.24e-05	0.00176	CcSEcCtD
Bosutinib—Pain—Carmustine—melanoma	6.24e-05	0.00176	CcSEcCtD
Bosutinib—PDGFRB—mammalian vulva—melanoma	6.23e-05	0.0016	CbGeAlD
Bosutinib—Body temperature increased—Dactinomycin—melanoma	6.16e-05	0.00174	CcSEcCtD
Bosutinib—Abdominal pain—Dactinomycin—melanoma	6.16e-05	0.00174	CcSEcCtD
Bosutinib—MAP4K4—lymph node—melanoma	6.13e-05	0.00158	CbGeAlD
Bosutinib—Decreased appetite—Temozolomide—melanoma	6.13e-05	0.00173	CcSEcCtD
Bosutinib—Cardiac disorder—Docetaxel—melanoma	6.13e-05	0.00173	CcSEcCtD
Bosutinib—ABL1—skin of body—melanoma	6.09e-05	0.00157	CbGeAlD
Bosutinib—Gastrointestinal disorder—Temozolomide—melanoma	6.09e-05	0.00172	CcSEcCtD
Bosutinib—BCR—lymph node—melanoma	6.09e-05	0.00156	CbGeAlD
Bosutinib—NUAK2—lymph node—melanoma	6.09e-05	0.00156	CbGeAlD
Bosutinib—Fatigue—Temozolomide—melanoma	6.08e-05	0.00172	CcSEcCtD
Bosutinib—MAP3K12—lymph node—melanoma	6.04e-05	0.00155	CbGeAlD
Bosutinib—Pain—Temozolomide—melanoma	6.03e-05	0.0017	CcSEcCtD
Bosutinib—Feeling abnormal—Carmustine—melanoma	6.01e-05	0.0017	CcSEcCtD
Bosutinib—Asthenia—Bleomycin—melanoma	6e-05	0.0017	CcSEcCtD
Bosutinib—Gastrointestinal pain—Carmustine—melanoma	5.97e-05	0.00169	CcSEcCtD
Bosutinib—Immune system disorder—Docetaxel—melanoma	5.96e-05	0.00169	CcSEcCtD
Bosutinib—Mediastinal disorder—Docetaxel—melanoma	5.95e-05	0.00168	CcSEcCtD
Bosutinib—STK35—lymph node—melanoma	5.92e-05	0.00152	CbGeAlD
Bosutinib—MAP2K1—lymph node—melanoma	5.92e-05	0.00152	CbGeAlD
Bosutinib—Pruritus—Bleomycin—melanoma	5.91e-05	0.00167	CcSEcCtD
Bosutinib—CSK—lymph node—melanoma	5.88e-05	0.00151	CbGeAlD
Bosutinib—CSNK1A1—lymph node—melanoma	5.84e-05	0.0015	CbGeAlD
Bosutinib—YES1—head—melanoma	5.82e-05	0.0015	CbGeAlD
Bosutinib—Feeling abnormal—Temozolomide—melanoma	5.81e-05	0.00164	CcSEcCtD
Bosutinib—HCK—lymph node—melanoma	5.81e-05	0.00149	CbGeAlD
Bosutinib—CLK1—lymph node—melanoma	5.81e-05	0.00149	CbGeAlD
Bosutinib—ABL2—lymph node—melanoma	5.77e-05	0.00148	CbGeAlD
Bosutinib—STK10—head—melanoma	5.77e-05	0.00148	CbGeAlD
Bosutinib—Abdominal pain—Carmustine—melanoma	5.77e-05	0.00163	CcSEcCtD
Bosutinib—Body temperature increased—Carmustine—melanoma	5.77e-05	0.00163	CcSEcCtD
Bosutinib—Gastrointestinal pain—Temozolomide—melanoma	5.77e-05	0.00163	CcSEcCtD
Bosutinib—TAOK3—head—melanoma	5.75e-05	0.00148	CbGeAlD
Bosutinib—Malnutrition—Docetaxel—melanoma	5.75e-05	0.00162	CcSEcCtD
Bosutinib—BMP2K—lymph node—melanoma	5.7e-05	0.00147	CbGeAlD
Bosutinib—CAMK2G—lymph node—melanoma	5.7e-05	0.00147	CbGeAlD
Bosutinib—LRRK2—lymph node—melanoma	5.65e-05	0.00145	CbGeAlD
Bosutinib—EGFR—lymph node—melanoma	5.63e-05	0.00145	CbGeAlD
Bosutinib—Dysgeusia—Docetaxel—melanoma	5.63e-05	0.00159	CcSEcCtD
Bosutinib—Urticaria—Temozolomide—melanoma	5.6e-05	0.00158	CcSEcCtD
Bosutinib—SRC—head—melanoma	5.6e-05	0.00144	CbGeAlD
Bosutinib—Asthenia—Dactinomycin—melanoma	5.59e-05	0.00158	CcSEcCtD
Bosutinib—Abdominal pain—Temozolomide—melanoma	5.57e-05	0.00158	CcSEcCtD
Bosutinib—Body temperature increased—Temozolomide—melanoma	5.57e-05	0.00158	CcSEcCtD
Bosutinib—Back pain—Docetaxel—melanoma	5.56e-05	0.00157	CcSEcCtD
Bosutinib—ABL1—mammalian vulva—melanoma	5.56e-05	0.00143	CbGeAlD
Bosutinib—PTK2B—lymph node—melanoma	5.5e-05	0.00142	CbGeAlD
Bosutinib—CSNK1E—lymph node—melanoma	5.42e-05	0.00139	CbGeAlD
Bosutinib—Diarrhoea—Dactinomycin—melanoma	5.33e-05	0.00151	CcSEcCtD
Bosutinib—SIK1—lymph node—melanoma	5.33e-05	0.00137	CbGeAlD
Bosutinib—IRAK4—lymph node—melanoma	5.33e-05	0.00137	CbGeAlD
Bosutinib—Vomiting—Bleomycin—melanoma	5.32e-05	0.0015	CcSEcCtD
Bosutinib—Anaemia—Docetaxel—melanoma	5.31e-05	0.0015	CcSEcCtD
Bosutinib—EPHA4—lymph node—melanoma	5.28e-05	0.00136	CbGeAlD
Bosutinib—Rash—Bleomycin—melanoma	5.27e-05	0.00149	CcSEcCtD
Bosutinib—Dermatitis—Bleomycin—melanoma	5.27e-05	0.00149	CcSEcCtD
Bosutinib—Asthenia—Carmustine—melanoma	5.24e-05	0.00148	CcSEcCtD
Bosutinib—ERBB3—lymph node—melanoma	5.23e-05	0.00134	CbGeAlD
Bosutinib—ULK3—lymph node—melanoma	5.21e-05	0.00134	CbGeAlD
Bosutinib—MAP2K2—lymph node—melanoma	5.21e-05	0.00134	CbGeAlD
Bosutinib—MAP3K2—lymph node—melanoma	5.18e-05	0.00133	CbGeAlD
Bosutinib—MAP2K5—head—melanoma	5.15e-05	0.00132	CbGeAlD
Bosutinib—Leukopenia—Docetaxel—melanoma	5.14e-05	0.00145	CcSEcCtD
Bosutinib—MAP3K7—lymph node—melanoma	5.13e-05	0.00132	CbGeAlD
Bosutinib—TBK1—lymph node—melanoma	5.07e-05	0.0013	CbGeAlD
Bosutinib—PTK2—lymph node—melanoma	5.07e-05	0.0013	CbGeAlD
Bosutinib—Asthenia—Temozolomide—melanoma	5.06e-05	0.00143	CcSEcCtD
Bosutinib—CSF1R—head—melanoma	5.03e-05	0.00129	CbGeAlD
Bosutinib—Cough—Docetaxel—melanoma	5.01e-05	0.00142	CcSEcCtD
Bosutinib—Diarrhoea—Carmustine—melanoma	4.99e-05	0.00141	CcSEcCtD
Bosutinib—Pruritus—Temozolomide—melanoma	4.99e-05	0.00141	CcSEcCtD
Bosutinib—IRAK1—lymph node—melanoma	4.97e-05	0.00128	CbGeAlD
Bosutinib—Nausea—Bleomycin—melanoma	4.97e-05	0.0014	CcSEcCtD
Bosutinib—Vomiting—Dactinomycin—melanoma	4.96e-05	0.0014	CcSEcCtD
Bosutinib—Rash—Dactinomycin—melanoma	4.92e-05	0.00139	CcSEcCtD
Bosutinib—Chest pain—Docetaxel—melanoma	4.89e-05	0.00138	CcSEcCtD
Bosutinib—Myalgia—Docetaxel—melanoma	4.89e-05	0.00138	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—melanoma	4.89e-05	0.00138	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—melanoma	4.88e-05	0.00125	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.86e-05	0.00137	CcSEcCtD
Bosutinib—FGR—lymph node—melanoma	4.85e-05	0.00125	CbGeAlD
Bosutinib—LCK—lymph node—melanoma	4.85e-05	0.00125	CbGeAlD
Bosutinib—AXL—lymph node—melanoma	4.83e-05	0.00124	CbGeAlD
Bosutinib—Dizziness—Carmustine—melanoma	4.83e-05	0.00136	CcSEcCtD
Bosutinib—Diarrhoea—Temozolomide—melanoma	4.82e-05	0.00136	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—melanoma	4.69e-05	0.00133	CcSEcCtD
Bosutinib—Oedema—Docetaxel—melanoma	4.69e-05	0.00133	CcSEcCtD
Bosutinib—Dizziness—Temozolomide—melanoma	4.66e-05	0.00132	CcSEcCtD
Bosutinib—Infection—Docetaxel—melanoma	4.66e-05	0.00132	CcSEcCtD
Bosutinib—SLK—lymph node—melanoma	4.65e-05	0.00119	CbGeAlD
Bosutinib—Vomiting—Carmustine—melanoma	4.64e-05	0.00131	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—melanoma	4.63e-05	0.00131	CcSEcCtD
Bosutinib—EPHB4—lymph node—melanoma	4.61e-05	0.00119	CbGeAlD
Bosutinib—Rash—Carmustine—melanoma	4.6e-05	0.0013	CcSEcCtD
Bosutinib—Nervous system disorder—Docetaxel—melanoma	4.6e-05	0.0013	CcSEcCtD
Bosutinib—Dermatitis—Carmustine—melanoma	4.6e-05	0.0013	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—melanoma	4.59e-05	0.0013	CcSEcCtD
Bosutinib—Headache—Carmustine—melanoma	4.57e-05	0.00129	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—melanoma	4.56e-05	0.00129	CcSEcCtD
Bosutinib—EPHA2—lymph node—melanoma	4.53e-05	0.00116	CbGeAlD
Bosutinib—FYN—lymph node—melanoma	4.52e-05	0.00116	CbGeAlD
Bosutinib—Vomiting—Temozolomide—melanoma	4.48e-05	0.00127	CcSEcCtD
Bosutinib—PDGFRB—head—melanoma	4.46e-05	0.00115	CbGeAlD
Bosutinib—Rash—Temozolomide—melanoma	4.45e-05	0.00126	CcSEcCtD
Bosutinib—Dermatitis—Temozolomide—melanoma	4.44e-05	0.00126	CcSEcCtD
Bosutinib—Headache—Temozolomide—melanoma	4.42e-05	0.00125	CcSEcCtD
Bosutinib—MAP3K3—lymph node—melanoma	4.41e-05	0.00114	CbGeAlD
Bosutinib—MAP4K5—lymph node—melanoma	4.41e-05	0.00114	CbGeAlD
Bosutinib—Nausea—Carmustine—melanoma	4.33e-05	0.00123	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Docetaxel—melanoma	4.27e-05	0.00121	CcSEcCtD
Bosutinib—Nausea—Temozolomide—melanoma	4.19e-05	0.00118	CcSEcCtD
Bosutinib—Dyspnoea—Docetaxel—melanoma	4.18e-05	0.00118	CcSEcCtD
Bosutinib—ABCB1—blood vessel—melanoma	4.09e-05	0.00105	CbGeAlD
Bosutinib—YES1—lymph node—melanoma	4.08e-05	0.00105	CbGeAlD
Bosutinib—Decreased appetite—Docetaxel—melanoma	4.08e-05	0.00115	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—melanoma	4.05e-05	0.00114	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—melanoma	4.04e-05	0.00114	CcSEcCtD
Bosutinib—STK10—lymph node—melanoma	4.04e-05	0.00104	CbGeAlD
Bosutinib—TAOK3—lymph node—melanoma	4.02e-05	0.00103	CbGeAlD
Bosutinib—Pain—Docetaxel—melanoma	4.01e-05	0.00113	CcSEcCtD
Bosutinib—ABL1—head—melanoma	3.98e-05	0.00102	CbGeAlD
Bosutinib—SRC—lymph node—melanoma	3.92e-05	0.00101	CbGeAlD
Bosutinib—Feeling abnormal—Docetaxel—melanoma	3.86e-05	0.00109	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—melanoma	3.83e-05	0.00108	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—melanoma	3.71e-05	0.00105	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—melanoma	3.71e-05	0.00105	CcSEcCtD
Bosutinib—MAP2K5—lymph node—melanoma	3.61e-05	0.000928	CbGeAlD
Bosutinib—CSF1R—lymph node—melanoma	3.52e-05	0.000905	CbGeAlD
Bosutinib—Asthenia—Docetaxel—melanoma	3.36e-05	0.000951	CcSEcCtD
Bosutinib—Pruritus—Docetaxel—melanoma	3.32e-05	0.000938	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—melanoma	3.21e-05	0.000907	CcSEcCtD
Bosutinib—PDGFRB—lymph node—melanoma	3.12e-05	0.000803	CbGeAlD
Bosutinib—Dizziness—Docetaxel—melanoma	3.1e-05	0.000876	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—melanoma	2.98e-05	0.000843	CcSEcCtD
Bosutinib—Rash—Docetaxel—melanoma	2.96e-05	0.000836	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—melanoma	2.95e-05	0.000835	CcSEcCtD
Bosutinib—Headache—Docetaxel—melanoma	2.94e-05	0.00083	CcSEcCtD
Bosutinib—Nausea—Docetaxel—melanoma	2.79e-05	0.000787	CcSEcCtD
Bosutinib—ABL1—lymph node—melanoma	2.78e-05	0.000716	CbGeAlD
Bosutinib—ABCB1—retina—melanoma	2.16e-05	0.000555	CbGeAlD
Bosutinib—ABCB1—mammalian vulva—melanoma	1.73e-05	0.000444	CbGeAlD
Bosutinib—ABCB1—head—melanoma	1.24e-05	0.000318	CbGeAlD
Bosutinib—ABCB1—lymph node—melanoma	8.66e-06	0.000223	CbGeAlD
Bosutinib—ERBB3—Signaling Pathways—IL6—melanoma	1.11e-07	1.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—melanoma	1.11e-07	1.17e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK1—melanoma	1.11e-07	1.17e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—melanoma	1.11e-07	1.17e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—melanoma	1.11e-07	1.17e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—melanoma	1.11e-07	1.17e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—melanoma	1.11e-07	1.17e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—melanoma	1.1e-07	1.17e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—melanoma	1.1e-07	1.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—melanoma	1.1e-07	1.17e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—melanoma	1.1e-07	1.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—melanoma	1.1e-07	1.16e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—melanoma	1.09e-07	1.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—melanoma	1.09e-07	1.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—melanoma	1.09e-07	1.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—melanoma	1.09e-07	1.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—melanoma	1.09e-07	1.15e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF2—melanoma	1.08e-07	1.14e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—melanoma	1.07e-07	1.13e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—melanoma	1.07e-07	1.13e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—melanoma	1.07e-07	1.13e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—melanoma	1.07e-07	1.13e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—melanoma	1.07e-07	1.13e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—melanoma	1.07e-07	1.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—melanoma	1.06e-07	1.13e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK1—melanoma	1.06e-07	1.13e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—melanoma	1.06e-07	1.12e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—melanoma	1.06e-07	1.12e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—melanoma	1.06e-07	1.12e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—melanoma	1.06e-07	1.12e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—melanoma	1.06e-07	1.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—melanoma	1.06e-07	1.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—melanoma	1.05e-07	1.11e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—melanoma	1.05e-07	1.11e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNA11—melanoma	1.05e-07	1.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—melanoma	1.05e-07	1.11e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—melanoma	1.05e-07	1.11e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—melanoma	1.05e-07	1.11e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—melanoma	1.04e-07	1.1e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—melanoma	1.04e-07	1.09e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—FASN—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—melanoma	1.03e-07	1.09e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—melanoma	1.02e-07	1.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—melanoma	1.02e-07	1.07e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—melanoma	1.01e-07	1.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—melanoma	1.01e-07	1.07e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—melanoma	1.01e-07	1.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—melanoma	1.01e-07	1.06e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—melanoma	1.01e-07	1.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—melanoma	1e-07	1.06e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—melanoma	1e-07	1.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—melanoma	1e-07	1.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—melanoma	9.99e-08	1.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—melanoma	9.98e-08	1.05e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—melanoma	9.97e-08	1.05e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—melanoma	9.94e-08	1.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—melanoma	9.93e-08	1.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK1—melanoma	9.92e-08	1.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—melanoma	9.92e-08	1.05e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—melanoma	9.92e-08	1.05e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—melanoma	9.91e-08	1.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—melanoma	9.91e-08	1.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—melanoma	9.9e-08	1.05e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NFKB1—melanoma	9.87e-08	1.04e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—melanoma	9.86e-08	1.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK1—melanoma	9.83e-08	1.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—melanoma	9.82e-08	1.04e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—melanoma	9.81e-08	1.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—melanoma	9.81e-08	1.04e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—melanoma	9.8e-08	1.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—melanoma	9.79e-08	1.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAQ—melanoma	9.79e-08	1.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD44—melanoma	9.79e-08	1.03e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—melanoma	9.77e-08	1.03e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—melanoma	9.76e-08	1.03e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—melanoma	9.69e-08	1.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK1—melanoma	9.69e-08	1.02e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—melanoma	9.68e-08	1.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—melanoma	9.68e-08	1.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—melanoma	9.68e-08	1.02e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—melanoma	9.65e-08	1.02e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—melanoma	9.63e-08	1.02e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—melanoma	9.62e-08	1.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—melanoma	9.59e-08	1.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—melanoma	9.58e-08	1.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—melanoma	9.56e-08	1.01e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—melanoma	9.54e-08	1.01e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—melanoma	9.53e-08	1.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NFKB1—melanoma	9.51e-08	1.01e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—melanoma	9.49e-08	1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK1—melanoma	9.48e-08	1e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—melanoma	9.48e-08	1e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—melanoma	9.45e-08	9.99e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—melanoma	9.41e-08	9.95e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—melanoma	9.4e-08	9.94e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1B1—melanoma	9.39e-08	9.92e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—melanoma	9.37e-08	9.91e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK1—melanoma	9.34e-08	9.87e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—melanoma	9.33e-08	9.87e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK1—melanoma	9.29e-08	9.82e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—melanoma	9.28e-08	9.81e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—melanoma	9.28e-08	9.81e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—melanoma	9.27e-08	9.8e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—melanoma	9.25e-08	9.77e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—melanoma	9.24e-08	9.76e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—melanoma	9.24e-08	9.76e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—melanoma	9.19e-08	9.72e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—melanoma	9.15e-08	9.67e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—melanoma	9.14e-08	9.66e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—melanoma	9.12e-08	9.64e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—melanoma	9.04e-08	9.56e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—melanoma	9.01e-08	9.53e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—melanoma	9.01e-08	9.52e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—melanoma	9e-08	9.51e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—melanoma	8.96e-08	9.47e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—melanoma	8.96e-08	9.47e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—melanoma	8.91e-08	9.42e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—melanoma	8.87e-08	9.38e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—melanoma	8.85e-08	9.36e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—melanoma	8.85e-08	9.36e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—melanoma	8.84e-08	9.35e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—melanoma	8.82e-08	9.32e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—melanoma	8.77e-08	9.27e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—melanoma	8.77e-08	9.27e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—melanoma	8.73e-08	9.23e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—melanoma	8.73e-08	9.22e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—melanoma	8.68e-08	9.18e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—melanoma	8.64e-08	9.13e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—melanoma	8.61e-08	9.1e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—melanoma	8.55e-08	9.04e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—melanoma	8.55e-08	9.04e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—melanoma	8.54e-08	9.03e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—melanoma	8.53e-08	9.02e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—melanoma	8.53e-08	9.02e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—melanoma	8.53e-08	9.01e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—melanoma	8.52e-08	9.01e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—melanoma	8.51e-08	9e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—melanoma	8.48e-08	8.97e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—melanoma	8.48e-08	8.96e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—melanoma	8.46e-08	8.95e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NFKB1—melanoma	8.42e-08	8.9e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	8.4e-08	8.88e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—melanoma	8.33e-08	8.81e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—melanoma	8.24e-08	8.71e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—melanoma	8.23e-08	8.7e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—melanoma	8.18e-08	8.64e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—melanoma	8.17e-08	8.64e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—melanoma	8.16e-08	8.63e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—melanoma	8.13e-08	8.59e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—melanoma	8.1e-08	8.56e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK1—melanoma	8.07e-08	8.53e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—melanoma	8.06e-08	8.52e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—melanoma	8.05e-08	8.51e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—melanoma	7.97e-08	8.42e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—melanoma	7.96e-08	8.41e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—melanoma	7.95e-08	8.4e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—melanoma	7.94e-08	8.4e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—melanoma	7.89e-08	8.34e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—melanoma	7.87e-08	8.32e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—melanoma	7.85e-08	8.3e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—melanoma	7.84e-08	8.28e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—melanoma	7.79e-08	8.24e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—melanoma	7.78e-08	8.22e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK1—melanoma	7.77e-08	8.22e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—melanoma	7.77e-08	8.21e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—melanoma	7.73e-08	8.17e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—melanoma	7.64e-08	8.08e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—melanoma	7.63e-08	8.06e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—melanoma	7.62e-08	8.05e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—melanoma	7.61e-08	8.05e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—melanoma	7.57e-08	8e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—melanoma	7.55e-08	7.98e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—melanoma	7.55e-08	7.98e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—melanoma	7.54e-08	7.97e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—melanoma	7.49e-08	7.92e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—melanoma	7.45e-08	7.88e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—melanoma	7.44e-08	7.87e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—melanoma	7.34e-08	7.76e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—melanoma	7.29e-08	7.7e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—melanoma	7.23e-08	7.64e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—melanoma	7.17e-08	7.58e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—melanoma	7.13e-08	7.54e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PRKCA—melanoma	7.11e-08	7.52e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—melanoma	7.06e-08	7.46e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—melanoma	7.04e-08	7.44e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—melanoma	7.03e-08	7.44e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—melanoma	7e-08	7.4e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—melanoma	6.97e-08	7.36e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—melanoma	6.93e-08	7.33e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK1—melanoma	6.88e-08	7.27e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—melanoma	6.88e-08	7.27e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—melanoma	6.87e-08	7.26e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—melanoma	6.87e-08	7.26e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—melanoma	6.77e-08	7.16e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—melanoma	6.74e-08	7.13e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—melanoma	6.72e-08	7.11e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—melanoma	6.62e-08	7e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—melanoma	6.58e-08	6.96e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—melanoma	6.52e-08	6.9e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—melanoma	6.5e-08	6.87e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—melanoma	6.48e-08	6.84e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—melanoma	6.24e-08	6.6e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—melanoma	6.2e-08	6.55e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—melanoma	5.99e-08	6.33e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—melanoma	5.97e-08	6.31e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—melanoma	5.97e-08	6.31e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—melanoma	5.78e-08	6.11e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—melanoma	5.72e-08	6.04e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—melanoma	5.57e-08	5.89e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—melanoma	5.52e-08	5.84e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—melanoma	5.51e-08	5.82e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—melanoma	5.38e-08	5.68e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—melanoma	5.29e-08	5.59e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—melanoma	4.9e-08	5.18e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—melanoma	4.88e-08	5.16e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—melanoma	4.84e-08	5.11e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—melanoma	4.27e-08	4.51e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—melanoma	4.23e-08	4.47e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—melanoma	4.22e-08	4.47e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—melanoma	3.69e-08	3.9e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—melanoma	3.45e-08	3.65e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—melanoma	2.6e-08	2.75e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—melanoma	2.13e-08	2.25e-07	CbGpPWpGaD
